Computational Multitarget Drug Discovery

Polypharmacology in Drug Discovery

Volumn , Issue , 2012, Pages 263-301

  Horst, Jeremy A ^a   Laurenzi, Adrian ^b   Bernard, Brady ^c   Samudrala, Ram ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

Author keywords

Computational methods and virtual hits; Ligand target, binding affinity in target elucidation; Multitarget

Indexed keywords

EID: 84886052068     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118098141.ch13     Document Type: Chapter

References (132)

1. Fleming, A. (1929), On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae, Br. J. Exp. Pathol. 10, 226-236.
2. Fleming, A.; Voureka, A.; Kramer, I. R.; Hughes, W. H. (1950), The morphology and motility of Proteus vulgaris and other organisms cultured in the presence of penicillin, J. Gen. Microbiol. 4, 257-269.
3. Schneider, G.; Fechner, U. (2005), Computer-based de novo design of drug-like molecules, Nature Rev Drug Discov. 4, 649-663.
4. DiMasi, J. A.; Hansen, R. W.; Grabowski, H. G. (2003), The price of innovation: new estimates of drug development costs, J Health Econ. 22(2), 151-185.
5. Adams, C.; Brantner, V. (2006), Estimating the cost of new drug development: Is it really 802 million dollars? Health Aff. (Millwood) 25(2), 420-428.
6. Jenwitheesuk, E.; Horst, J. A.; Rivas, K. L.; Van Voorhis, W. C.; Samudrala, R. (2008), Novel paradigms for drug discovery: Computational multitarget screening, Trends Pharmacol. Sci. 29(2), 62-71.
7. Costin, J. M.; Jenwitheesuk, E.; Lok, S.-M.; Hunsperger, E.; Conrads, K. A.; Fontaine, K. A.; Rees, C. R.; Rossmann, M. G.; Isern, S.; Samudrala, R.; Michael, S. F. (2010), Structural optimization and de novo design of dengue virus entry inhibitory peptides, PLoS Negl. Trop. Dis. 4, e721.
8. Jenwitheesuk, E.; Samudrala, R. (2007), Identification of potential HIV-1 targets of minocycline, Bioinformatics 23(20), 2797-2799.
9. Keiser, M. J.; Setola, V.; Irwin, J. J.; Laggner, C.; Abbas, A. I.; Hufeisen, S. J.; Jensen, N.H.;Kuijer,M.B.;Matos,R.C.;Tran,T. B.;Whaley, R.;Glennon, R. A.;Hert, J.;Thomas, K. L.;Edwards,D.D.; Shoichet,B.K.; Roth, B. L. (2009), Predicting newmolecular targets for known drugs, Nature 462, 175-181.
10. Rogawski, M. A. (2000), Lowaffinity channel blocking (uncompetitive)NMDA receptor antagonists as therapeutic agents-towards an understanding of their favorable tolerability, Amino Acids 19, 133-149.
11. Nezami, A.; Kimura, T.; Hidaka, K.; Kiso, A.; Liu, J.; Kiso,Y.; Goldberg,D. E.; Freire, E. (2003), High-affinity inhibition of a family of Plasmodium falciparum proteases by a designed adaptive inhibitor, Biochemistry 42(28), 8459-8464.
12. Csermely, P.; Agoston, V.; Pongor, S. (2005), The efficiency of multi-target drugs: The network approach might help drug design, Trends Pharmacol. Sci. 26, 187-182.
13. Samudrala, R.; Jenwitheesuk, E. (2007), Identification of potential HIV-1 targets of minocycline, Bioinformatics 23, 2797-2799.
14. de Vos, P. (2010), European materia medica in historical texts: Longevity of a tradition and implications for future use, J. Ethnopharmacol. 132(1), 28-47.
15. Campbell, J.; Campbell, J.; David, R. (2005), An insight into the practice of pharmacy in ancient Egypt, Pharm. Hist. 35(4), 62-68.
16. Manniche, L., An Ancient Egyption Herbal, British Museum Publications Ltd., London, 1989.
17. Huff, T., The Rise of Early Modern Science: Islam, China, and the West, Cambridge University Press, 2003.
18. Hamilton, G. R.; Baskett, T. F. (2000), In the arms of Morpheus the development of morphine for postoperative pain relief, Can. J. Anaesth. 47(4), 367-374.
19. Ehrlich, P. (1910), Die behandlung der syphilis mit dem ehrlichschen präparat 606, Dsch. Med. Wochenschrift 1893-1896.
20. Lloyd, N. C.; Morgan, H.W.; Nicholson, B. K.; Ronimus, R. S. (2005), The composition of Ehrlich's salvarsan: Resolution of a century-old debate, Angew. Chem. Intnatl. Ed. Engl. 44(6), 941-4.
21. Strebhardt, K.; Ullrich, A. (2008), Paul Ehrlich's magic bullet concept: 100 years of progress, Nature Rev. Cancer 8(6), 473-480.
22. Plouffe, D.; Brinker, A.; McNamara, C.; Henson, K.; Kato, N.; Kuhen, K.; Nagle, A.; Adrián, F.; Matzen, J. T.; Anderson, P.; Nam, T. G.; Gray, N. S.; Chatterjee, A.; Janes, J.; Yan, S. F.; Trager, R.; Caldwell, J. S.; Schultz, P. G.; Zhou, Y.;Winzeler, E. A. (2008), In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen, Proc. Natl. Acad. Sci. USA 105, 9059-9064.
23. Chong,C. R.; Chen, X.; Shi, L.; Liu, J.O.; Sullivan, D. J., Jr., (2006),Aclinical drug library screen identifies astemizole as an antimalarial agent, Nature Chem. Biol. 2, 415-416.
24. Weisman, J. L.; Liou, A. P.; Shelat, A. A.; Cohen, F. E.; Guy, R. K.; DeRisi, J. L. (2006), Searching for new antimalarial therapeutics amongst known drugs, Chem. Biol. Drug Design 67, 409-416.
25. Schreiber, S.L. (2000), Target-oriented and diversity-oriented organic synthesis in drug discovery. Science, 287(5460), 1964-1969.
26. Abdi, M. H.; Beswick, P. J.; Billinton, A.; Chambers, L. J.; Charlton, A.; Collins, S. D.; Collis, K. L.; Dean, D. K.; Fonfria, E.; Gleave, R. J.; Lejeune, C. L.; Livermore, D. G.; Medhurst, S. J.; Michel, A. D.; Moses, A. P.; Page, L.; Patel, S.; Roman, S. A.; Senger, S.; Slingsby, B.; Steadman, J. G.; Stevens, A. J.; Walter, D. S. (2010), Discovery and structure-activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 receptor, BioMed Central Lett. 20, 5080-5084.
27. Cammarata, A.; Menon, G. K. (1976), Pattern recognition. Classification of therapeutic agents according to pharmacophores, J. Med. Chem. 19(6), 739-748.
28. Hansch, C. (1969), Quantitative approach to biochemical structure-activity relationships, Acc. Chem. Res. 2(8), 232-239.
29. Cupido, T.; Tulla-Puche, J.; Spengler, J.; Albericio, F. (2007), The synthesis of naturally occurring peptides and their analogs, Curr. Opin. Drug. Discov. Devel. 10(6), 768-83.
30. Ortí, L.; Carbajo, R. J.; Pieper, U.; Eswar, N.; Maurer, S. M.; Rai, A. K.; Taylor, G.; Todd, M. H.; Pineda-Lucena, A.; Sali, A.; Marti-Renom, M. A. (2009),Akernel for open source drug discovery in tropical diseases, PLoS Negl. Trop. Dis. 3(4), e418.
31. Borisy, A. A.; Elliott, P. J.; Hurst, N.W.; Lee, M. S.; Lehar, J.; Price, E. R.; Serbedzija, G.; Zimmermann, G. R.; Foley, M. A.; Stockwell, B. R.; Keith, C. T. (2003), Systematic discovery of multicomponent therapeutics, Proc. Natl. Acad. Sci. USA 100: 7977-7982.
32. Becker, O. M.; Marantz, Y.; Shacham, S.; Inbal, B.; Heifetz, A.; Kalid, O.; Bar-Haim, S.; Warshaviak, D.; Fichman, M.; Noiman S. (2004), G protein-coupled receptors: In silico drug discovery in 3D, Proc. Natl. Acad. Sci. USA 101(31), 11304-11309.
33. Natoli, T. A.; Smith, L. A.; Rogers, K. A.; Wang, B.; Komarnitsky, S.; Budman, Y.; Belenky, A.; Bukanov,N. O.; Dackowski,W. R.; Husson, H.; Russo, R. J.; Shayman, J. A.; Ledbetter, S. R.; Leonard, J. P.; Ibraghimov-Beskrovnaya, O. (2010), Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models, Nature Med. 16(7), 788-792.
34. Jensen, R. A. (1976), Enzyme recruitment in evolution of new function, Annu. Rev. Microbiol. 30, 409-425.
35. Khersonsky, O.; Roodveldt, C.; Tawfik, D. S. (2006), Enzyme promiscuity: Evolutionary and mechanistic aspects, Curr. Opin. Chem. Biol. 10(5), 498-508.
36. Horst, J. A.;Wang, K.; Horst, O.V.; Cunningham, M. L.; Samudrala, R. (2010),Disease risk of missense mutations using structural inference from predicted function, Curr. Protein Pept. Sci. 11(7), 500-515.
37. Jenwitheesuk, E.;Wang, K.; Mittler, J. E.; Samudrala, R. (2005), PIRSpred: Aweb server for reliable HIV-1 protein-inhibitor resistance/susceptibility prediction, Trends Microbiol. 13(4), 150-151.
38. Ekins, S. (2005), Systems-ADME/Tox: Resources and network approaches, J. Pharmacol. Toxicol. Meth. 53(1), 38-66.
39. Bellmann-Sickert, K.; Beck-Sickinger, A. G. (2010), Peptide drugs to target G proteincoupled receptors, Trends Pharmacol. Sci. 9, 434-441.
40. Noble, M. E.; Endicott, J. A.; Johnson, L. N. (2004), Protein kinase inhibitors: insights into drug design from structure, Science. 303(5665), 1800-1805.
41. Becker, O. M.; Dhanoa, D. S.; Marantz, Y.; Chen, D.; Shacham, S.; Cheruku, S.; Heifetz, A.; Mohanty, P.; Fichman, M.; Sharadendu, A.; Nudelman, R.; Kauffman, M.; Noiman, S. (2006), An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression, J. Med. Chem. 49(11), 3116-3135.
42. Desai, P. V.; Patny, A.; Sabnis, Y.; Tekwani, B.; Gut, J.; Rosenthal, P.; Srivastava, A.; Avery, M. (2004), Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The ChemBridge database, J. Med. Chem. 47(26), 6609-6615.
43. Desai, P. V.; Patny, A.; Gut, J.; Rosenthal, P. J.; Tekwani, B.; Srivastava, A.; Avery, M. (2006), Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory, J. Med. Chem. 49(5), 1576-1584.
44. de Paulis, T.; Reinhard, J. F., Jr., ; Oshana, S.; Kauffman, M.; Donahue, S. (2007), Tolerability, pharmacokinetics, and neuroendocrine effects of PRX-00023, a novel 5-HT1A agonist, in healthy subjects J. Clin. Pharmacol. 47, 817-824.
45. Rickels, K.; Mathew, S.; Banov, M. D.; Zimbroff, D. L.; Oshana, S.; Parsons, E. C. Jr.; Donahue, S. R.; Kauffman, M.; Iyer, G. R.; Reinhard, J. F. Jr., (2008), Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: Results of a double-blind, placebo-controlled trial, J. Clin. Psychopharmacol. 28, 235-239.
46. Hirschel, B.; Francioli, P. (1998), Progress and problems in the fight against AIDS, New Engl. J. Med. 338(13), 906-908.
47. Doman, T. N.; McGovern, S. L.;Witherbee, B. J.; Kasten, T. P.; Kurumbail, R.; Stallings, W. C.; Connolly, D. T.; Shoichet, B. K. (2002), Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B, J. Med. Chem. 45(11), 2213-2221.
48. Chong, C. R.; Chen, X.; Shi, L.; Liu, J. O.; Sullivan, D. J., Jr., (2006), A clinical drug library screen identifies astemizole as an antimalarial agent, Nat. Chem. Biol. 2(8), 415-416.
49. Weisman, J. L.; Liou, A. P.; Shelat, A. A.; Cohen, F. E.; Guy, R. K.; DeRisi, J. L. (2006), Searching for new antimalarial therapeutics amongst known drugs, Chem. Biol. Drug. Des. 67(6), 409-416.
50. Babaoglu, K.; Simeonov, A.; Irwin, J. J.; Nelson, M. E.; Feng, B.; Thomas, C. J.; Cancian, L.; Costi,M. P.;Maltby, D. A.; Jadhav, A.; Inglese, J.; Austin, C. P.; Shoichet, B. K. (2008), Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase, J. Med. Chem. 51(8), 2502-2511.
51. Kato, N.; Sakata, T.; Breton, G.; Le Roch, K. G.; Nagle, A.; Andersen, C.; Bursulaya, B.; Henson, K.; Johnson, J.; Kumar, K. A.; Marr, F.; Mason, D.; McNamara, C.; Plouffe, D.; Ramachandran, V.; Spooner, M.; Tuntland, T.; Zhou, Y.; Peters, E. C.; Chatterjee, A.; Schultz, P. G.;Ward, G. E.;, Gray, N.; Harper, J.;Winzeler, E.A. (2008), Gene expression signatures and small-molecule compounds link a protein kinase to Plasmodium falciparum motility, Nat. Chem. Biol. 4(6), 347-356.
52. Gamo, F. J.; Sanz, L. M.;Vidal, J.; de Cozar, C.; Alvarez, E.; Lavandera, J. L.;Vanderwall, D. E.; Green, D. V.; Kumar, V.; Hasan, S.; Brown, J. R.; Peishoff, C. E.; Cardon, L. R.; Garcia-Bustos, J. F. (2010), Thousands of chemical starting points for antimalarial lead identification, Nature. 465(7296), 305-310.
53. Sarmiento, M.; Wu, L.; Keng, Y. F.; Song, L.; Luo, Z.; Huang, Z.; Wu, GZ.; Yuan, AK.; Zhang, Z. Y. (2000), Structure-based discovery of small molecule inhibitors targeted to protein tyrosine phosphatase 1B, J. Med. Chem. 43(2), 146-155.
54. Grzybowski, B. A.; Ishchenko, A. V.; Kim, C. Y.; Topalov, G.; Chapman, R.; Christianson, D. W.; Whitesides, G. M.; Shakhnovich, E. I. (2002), Combinatorial computational method gives new picomolar ligands for a known enzyme, Proc. Natl. Acad. Sci. U. S. A. 99(3), 1270-1273.
55. Nezami, A.; Luque, I.; Kimura, T.; Kiso, Y.; Freire, E. (2002), Identification and characterization of allophenylnorstatine-based inhibitors of plasmepsin II, an antimalarial target, Biochemistry. 41(7), 2273-2280.
56. Nezami, A.; Kimura, T.; Hidaka, K.; Kiso, A.; Liu, J.; Kiso, Y.; Goldberg, DE.; Freire, E. (2002), High-affinity inhibition of a family of Plasmodium falciparum proteases by a designed adaptive inhibitor. Biochemistry. 42(28), 8459-8464.
57. Desai, PV.; Patny, A.; Sabnis, Y.; Tekwani, B.; Gut, J.; Rosenthal, P.; Srivastava, A.; Avery, M.; (2008), Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The ChemBridge database. J. Med. Chem. 47(26), 6609-6615.
58. Desai, P. V.; Patny, A.; Gut, J.; Rosenthal, P. J.; Tekwani, B.; Srivastava, A.; Avery,M.; (2003), Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory. J. Med. Chem. 49(5), 1576-1584.
59. Babaoglu, K,; Simeonov, A.; Irwin, J. J.; Nelson, M. E.; Feng, B.; Thomas, C. J.; Cancian, L.; Costi, M. P.; Maltby, D. A.; Jadhav, A.; (2008), Inglese J, Austin C. P, Shoichet BK. Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase. J. Med. Chem. 51(8), 2502-2511.
60. Jenwitheesuk, E.; Horst, J. A.; Rivas, K. L.; Van, Voorhis,W. C.; Samudrala, R., (2008), Novel paradigms for drug discovery: computational multitarget screening. Trends. Pharmacol. Sci. 29(2), 62-71.
61. L. Orti, R. J.; Carbajo, U.; Pieper, N.; Eswar, S. M.; Maurer, A. K.; Rai, G.; Taylor,M. H.; Todd, A.; Pineda-Lucena, A.; Sali, M.A.; Marti-Renom, (2009), A kernel for the Tropical Disease Initiative. Nat. Biotechnol. 27, 320-321.
62. Costin, J. M.; Jenwitheesuk, E.; Lok, S. M.; Hunsperger, E.; Conrads, K. A.; Fontaine, K. A.; Rees, C. R.; Rossmann, M. G.; Isern, S.; Samudrala, R.; Michael, S. F.; (2010), Structural optimization and de novo design of dengue virus entry inhibitory peptides. PLoS. Negl. Trop. Dis. 4(6), e721.
63. Moult, J. (2005), A decade of CASP: Progress, bottlenecks and prognosis in protein structure prediction, Curr. Opin. Struct. Biol. 15(3), 285-289.
64. Kitchen, D. B.; Decornez, H.; Furr, J. R.; Bajorath, J. (2004), Docking and scoring in virtual screening for drug discovery: Methods and applications, Nature Rev. Drug Discov. 3, 935-949.
65. Bernard, B.; Samudrala, R. (2009), A generalized knowledge-based discriminatory function for biomolecular interactions, Proteins 76: 115-128.
66. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. (2000), The Protein Data Bank, Nucl. Acids Res. 28: 235-242.
67. Koshland, D. E. (1958), Application of a theory of enzyme specificity to protein synthesis, Proc. Natl. Acad. Sci. USA 44(2), 98-104.
68. Kuntz, I. D.; Blaney, J. M.; Oatley, S. J.; Langridge, R.; Ferrin, T. E. (1982), A geometric approach to macromolecular-ligand interactions, J. Mol. Biol. 161, 269-288.
69. Plewczynski, D.; Laźniewski, M.; Augustyniak, R.; Ginalski K. (2010), Can we trust docking results? Evaluation of seven commonly used programs on PDBbind database, J. Comput. Chem. 4, 742-755.
70. Ewing, T. J.; Makino, S.; Skillman, A. G.; Kuntz, I. D. (2001), DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases J. Comput.-Aid. Mol. Design 15, 411-428.
71. Lennard-Jones, J. E. (1924), On the determination of molecular fields, Proc. Roy. Soc. Lond. A 106(738), 463-477.
72. Weiner, S. J.;Kollman, P. A.; Case, D. A.; Singh, U. C.; Ghio, C.; Alagona, G.; Profeta, S., Jr., ;Weiner, P. J. (1984),Anewforce field for molecular mechanical simulation of nucleic acids and proteins, J. Am. Chem. Soc. 106, 765-784.
73. Ponder, J.W.; Case, D. A. (2003), Force fields for protein simulations, Adv. Protein Chem. 66, 27-85.
74. Case, D. A.; Cheatham, T. E. 3rd; Darden, T.; Gohlke, H.; Luo, R.; Merz, K. M., Jr.; Onufriev, A.; Simmerling, C.; Wang, B.; Woods, R. J. (2005), The Amber biomolecular simulation programs, J. Comput. Chem. 26(16), 1668-1688.
75. Jenwitheesuk, E.; Samudrala, R. (2003), Identifying inhibitors of the SARS coronavirus proteinase, BioMed Central Lett. 13(22), 3989-3992.
76. Ngan, S.-C.; Inouye, M.; Samudrala, R. (2006), A knowledge-based scoring function based on residue triplets for protein structure prediction, Protein Eng. Design Select. 19, 187-193.
77. Allen, F. H. (2002), The Cambridge Structural Database: A quarter of a million crystal structures and rising, Acta Crystallogr. B. 58(3), 380-388.
78. Fan, H.; Irwin, J. J.;Webb, B. M.; Klebe, G.; Shoichet, B. K.; Sali, A. (2009), Molecular docking screens using comparative models of proteins, J. Chem. Inform. Model. 49(11):2512-2527.
79. Abdel-Rahman, H. M.; Kimura, T.; Hidaka, K.; Kiso, A.; Nezami, A.; Freire, E.; Hayashi, Y.; Kiso, Y. (2004), Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases Biol. Chem. 385(11), 1035-1039.
80. Nezami, A.; Laque, I.; Kimura, T.; Kiso, Y.; Freire, E. (2002), Identification and characterization of allophenylnorstatine-based inhibitors of plasmepsin II, an antimalarial target, Biochemistry 41, 2273-2280.
81. Gold, N. D.; Jackson, R. M. (2006), SitesBase: Fold independent structural comparisons of protein-ligand binding sites for exploring functional relationships, J. Mol. Biol. 355, 1112-1124.
82. Das, S.; Kokardekar, A.; Breneman, C. M. (2009), Rapid comparison of protein binding site surfaces with property encoded shape distributions, J. Chem. Inform. Model. 49, 2863-2872.
83. Weill, N.; Rognan, D. (2009), Development and validation of a novel protein-ligand fingerprint to mine chemogenomic space: Application toGprotein-coupled receptors and their ligands, J. Chem. Inform. Model. 49(4), 1049-1062.
84. Chen, B. Y.; Honig, B. (2010), VASP: Avolumetric analysis of surface properties yields insights into protein-ligand binding specificity, PLoS Comput. Biol. 6, e1000881.
85. Wang, K.; Samudrala, R. (2006), Incorporating background frequency improves entropybased residue conservation measures, BioMed Central Bioinform. 7, 385.
86. Horst, J. A.; Samudrala, R. (2010), A protein sequence meta-functional signature for calcium binding residue prediction, Pattern Recogn. Lett. 31(14), 2103-2112.
87. Greaves, R.;Warwicker, J. (2005), Active site identification through geometry-based and sequence profile-based calculations: Burial of catalytic clefts, J. Mol. Biol. 349(3), 547-557.
88. Gutteridge, A.; Thornton, J. M. (2005), Understanding nature's catalytic toolkit, Trends Biochem. Sci. 30, 622-629. Grzybowski, B. A.; Ishchenko, A.V.; Kim, C.Y.; Topalov, G.; Chapman, R.; Christianson, D. W.; Whitesides, G. M.; Shakhnovich, E. I. (2002), Combinatorial computational method gives new picomolar ligands for a known enzyme, Proc. Natl. Acad. Sci. USA 99(3), 1270-1273.
89. Lopez, G.; Ezkurdia, I.; Tress, M. L. (2009), Assessment of ligand binding residue predictions in CASP8, Proteins 77 (Suppl. 9), 138-146.
90. Roy, A.; Kucukural, A.; Zhang Y. (2010), I-TASSER: A unified platform for automated protein structure and function prediction, Nature Protoc. 5, 725-738.
91. Berezin, C.; Glaser, F.; Rosenberg, Y.; Paz, I.; Pupko, T.; Fariselli, P.; Casadio, R.; Ben-Tal, N. (2004), ConSeq: The identification of functionally and structurally important residues in protein sequences, Bioinformatics 20, 1322-1324.
92. Fischer, J. D.; Mayer, C. E.; Söding, J. (2008), Prediction of protein functional residues from sequence by probability density estimation, Bioinformatics 24(5), 613-620.
93. Wang, K.; Horst, J. A.; Cheng, G.; Nickle, D. C.; Samudrala, R. (2008), Protein metafunctional signatures from combining sequence, structure, evolution, and amino acid property information. PLoS. Comput. Biol. 4(9), e1000181.
94. Landau, M.; Mayrose, I.; Rosenberg, Y.; Glaser, F.; Martz, E.; Pupko, T.; Ben-Tal, N. (2005), ConSurf 2005: The projection of evolutionary conservation scores of residues on protein structures, Nucl. Acids Res. 33, W299-W302.
95. Ashworth, J.; Havranek, J. J.; Duarte, C. M.; Sussman, D.; Monnat, R. J, Jr.; Stoddard, B. L.; Baker, D., (2006), Computational redesign of endonuclease DNA binding and cleavage specificity. Nature. 441(7093), 656-659.
96. Jiang, L.; Althoff, E. A.; Clemente, F. R.; Doyle, L.; Ršthlisberger, D.; Zanghellini, A.; Gallaher, J. L.; Betker, J. L.; Tanaka, F.; Barbas C. F., 3rd, Hilvert, D.; Houk, K. N.; Stoddard, BL.; Baker, D, (2008), De novo computational design of retro-aldol enzymes. Science. 319(5868), 1387-1391.
97. Zhang, Y. (2008), I-TASSER server for protein 3D structure prediction, BioMed Central. Bioinform. 9, 40.
98. Zhang, Y.; Devries, M. E.; Skolnick, J. (2006), Structure modeling of all identified G protein-coupled receptors in the human genome, PLoS Comput. Biol. 2(2), e13.
99. Liu, T.; Horst, J. A.; Samudrala, R. (2009), A novel method for predicting and using distance constraints of high accuracy for refining protein structure prediction, Proteins 77, 220-234.
100. Michino,M.; Abola, E; Brooks, C. L., 3rd, Dixon, J. S.;Moult, J.; Stevens, R. C. GPCR Dock 2008 participants; (2009), Community-wide assessment of GPCR structure modelling and ligand docking: GPCR Dock 2008, Nature Rev. Drug Discov. 8(6), 455-463.
101. Hopkins, A. L. (2008), Network pharmacology: The next paradigm in drug discovery, Nature Chem. Biol. 4: 682-690.
102. Kohanski, M. A.; Dwyer, D. J.; Collins, J. J.; How antibiotics kill bacteria: from targets to networks. Nat Rev Microbiol. 8(6), 423-35.
103. Dancík, V.; Seiler, K. P.; Young, D.W.; Schreiber, S. L.; Clemons, P. A. (2010), Distinct biological network properties between the targets of natural products and disease genes, J. Am. Chem. Soc. 132(27), 9259-9261.
104. Newman, D. J.; Cragg, G. M. (2007), Natural products as sources of new drugs over the last 25 years, J. Nat. Prod. 70(3), 461-477.
105. Corey, E. J.; Long, A. K.; Rubenstein, S. D.; (1985) Computer-assisted analysis in organic synthesis. Science. 228(4698), 408-418.
106. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J., (1997), Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001 Mar. 46(1-3):3-26.
107. Gamo, F. J.; Sanz, L. M.;Vidal, J.; de Cozar, C.; Alvarez, E.; Lavandera, J. L.;Vanderwall, D. E.; Green, D. V.; Kumar, V.; Hasan, S.; Brown, J. R.; Peishoff, C. E.; Cardon, L. R.; Garcia-Bustos J. F. (2010), Thousands of chemical starting points for antimalarial lead identification, Nature 465(7296), 305-310.
108. Hidvegi, T.; Ewing, M.; Hale, P.; Dippold, C.; Beckett, C.; Kemp, C.; Maurice, N.; Mukherjee, A.; Goldbach, C.;Watkins, S.; Michalopoulos, G.; Perlmutter, D. H. (2010), An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis, Science 329(5988), 229-232.
109. Jenwitheesuk, E.; Samudrala, R. (2003), Improved prediction of HIV-1 proteaseinhibitor binding energies by molecular dynamics simulations, BioMed Centeral Structural Biology, 3, 2.
110. Jenwitheesuk, E.; Samudrala, R. (2005), Identification of potential multitarget antimalarial drugs, JAMA 294(12), 1490-1491.
111. Xie, L.;Wang, J.; Bourne, P. E. (2007), In silico elucidation of the molecular mechanism defining the adverse effect of selective estrogen receptor modulators, PLoS Comput. Biol. 3, e217.
112. Keiser, M. J.; Roth, B. L.; Armbruster, B. N.; Ernsberger, P.; Irwin, J. J.; Shoichet, BK.; (2007), Relating protein pharmacology by ligand chemistry. Nat Biotechnol. 25(2), 197-206.
113. Eckert, H.; Bajorath, J. (2007), Molecular similarity analysis in virtual screening: Foundations, limitations and novel approaches, Drug Discov. Today 12, 225-233.
114. Xie, L.; Bourne, P. E. (2005), Functional coverage of the human genome by existing structures, structural genomics targets, and homology models, PLoS Comput. Biol. 1, e31.
115. Walian, P.; Cross, T. A.; Jap. B. K.; (2004), Structural genomics of membrane proteins. Genome Biol. 5(4), 215.
116. Gudermann, T.; NŸrnberg, B.; Schultz, G. (1995), Receptors and G proteins as primary components of transmembrane signal transduction. Part 1. G-protein-coupled receptors: structure and function. J. Mol Med. 73(2), 51-63.
117. UniProt, Consortium.; (2007) The universal protein resource (UniProt). Nucleic Acids Res. 36(Database issue), D190-5.
118. Luque, I.; Freire, E. (2002), Structural parameterization of the binding enthalpy of small ligands, Proteins 49(2), 181-190.
119. Freire, E. (2009), A thermodynamic approach to the affinity optimization of drug candidates, Chem. Biol. Drug Design 74(5), 468-72.
120. Ladbury, J. E.; Klebe, G.; Freire, E. (2010), Adding calorimetric data to decision making in lead discovery: A hot tip, Nature Rev. Drug Discov. 9(1), 23-7.
121. Freire, E. (2008), Do enthalpy and entropy distinguish first in class from best in class? Drug Discov. Today 13(19-20), 869-874.
122. Kawasaki, Y.; Chufan, E. E.; Lafont, V.; Hidaka, K.; Kiso, Y.; Mario Amzel, L.; Freire, E. (2010), How much binding affinity can be gained by filling a cavity? Chem. Biol. Drug Design 75(2), 143-151.
123. Babaoglu, K.; Simeonov, A.; Irwin, J. J.; Nelson, M. E.; Feng, B.; Thomas, C. J.; Cancian, L.; Costi, M. P.; Maltby, D. A.; Jadhav, A.; Inglese, J.; Austin, C. P.; Shoichet, B. K. (2008), Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase, J. Med. Chem. 51(8), 2502-2511.
124. Deayton, J.; Mocroft, A.;Wilson, P.; Emery,V. C.; Johnson, M. A.; Griffiths, P. D. (1999), Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy, AIDS 13(10), 1203-1206.
125. Reed, J. B.; Morse, L. S. (1998), CMV retinitis and the controversies associated with highly active antiretroviral therapy and the immune recovery hypothesis, AIDS Patient Care STDs 12(3), 181-185.
126. Wang, K.; Jenwitheesuk, E.; Samudrala, R.; Mittler, J. E. (2004), Simple linear model provides highly accurate genotypic predictions of HIV-1 drug resistance, Antivir. Ther. 9(3), 343-352.
127. Jenwitheesuk, E.; Wang, K.; Mittler, J. E.; Samudrala, R. (2004), Improved accuracy of HIV-1 genotypic susceptibility interpretation using a consensus approach, AIDS 18(13), 1858-1859.
128. Jenwitheesuk, E.; Samudrala, R. (2005), Virtual screening of HIV-1 protease inhibitors against human cytomegalovirus protease using docking and molecular dynamics, AIDS 19(5), 529-531.
129. Ehrlich, P. (1911), Aus theorie und praxis der chemotherapie, Folia Serologica 7, 697-714.
130. Kaelin, W. G., Jr., (2004), Gleevec: Prototype or outlier? Sci STKE. 16 (225), pe12.
131. Peters, J. U.; Schnider, P.; Mattei, P.; Kansy, M. (2009), Pharmacological promiscuity: Dependence on compound properties and target specificity in a set of recent Roche compounds, ChemMedChem 4(4), 680-686.
132. Huang, S. (2002), Rational drug discovery: What can we learn from regulatory networks? Drug Discov. Today 7, S163-S169.